CytomX Therapeutics, Inc.
CTMX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $86,972 | $114,403 | $105,184 | $277,756 |
| - Cash | $38,052 | $17,171 | $193,650 | $205,530 |
| + Debt | $9,385 | $13,974 | $18,057 | $18,056 |
| Enterprise Value | $58,305 | $111,206 | -$70,409 | $90,282 |
| Revenue | $138,103 | $101,214 | $53,163 | $37,312 |
| % Growth | 36.4% | 90.4% | 42.5% | – |
| Gross Profit | $138,103 | $101,214 | $53,163 | $37,312 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | $26,763 | -$4,309 | -$98,892 | -$113,336 |
| % Margin | 19.4% | -4.3% | -186% | -303.8% |
| Net Income | $31,869 | -$569 | -$99,317 | -$115,870 |
| % Margin | 23.1% | -0.6% | -186.8% | -310.5% |
| EPS Diluted | 0.38 | -0.008 | -1.48 | -1.26 |
| % Growth | 5,035.1% | 99.5% | -17.5% | – |
| Operating Cash Flow | -$86,231 | -$56,035 | -$110,788 | -$119,031 |
| Capital Expenditures | -$310 | -$840 | -$1,740 | -$1,609 |
| Free Cash Flow | -$86,541 | -$56,875 | -$112,528 | -$120,640 |